John M. Kovarik

mTOR inhibition improves immune function in the elderly

Joan B. Mannick, Giuseppe Del Giudice, Maria Lattanzi et al. · Science Translational Medicine · 2014 · 735 citations

Aging, Immunology, Immunotherapy +17

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors

Anne O’Donnell, Sandrine Faivre, Howard A. Burris et al. · Journal of Clinical Oncology · 2008 · 476 citations

Reduced Inter- and Intraindividual Variability in Cyclosporine Pharmacokinetics from a Microemulsion Formulation

John M. Kovarik, Edgar A. Mueller, Klaus Kutz et al. · Journal of Pharmaceutical Sciences · 1994 · 297 citations

Pharmaceutical Science, Physiologically-based Pharmacokinetic Modeling, Medicine +6

CYCLOSPORINE PHARMACOKINETICS AND VARIABILITY FROM A MICROEMULSION FORMULATION—A MULTICENTER INVESTIGATION IN KIDNEY TRANSPLANT PATIENTS

John M. Kovarik, Edgar A. Mueller, Johannes B. van Bree et al. · Transplantation · 1994 · 251 citations

Pharmaceutical Science, Urology, Pharmacokinetic Modeling +12

Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data

Chiaki Tanaka, Terence O’Reilly, John M. Kovarik et al. · Journal of Clinical Oncology · 2008 · 209 citations